Financial Architects (New Jersey)’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-74
Closed -$5K – 630
2020
Q2
$5K Buy
74
+1
+1% +$60 ﹤0.01% 729
2020
Q1
$4K Hold
73
– – ﹤0.01% 734
2019
Q4
$5K Hold
73
– – ﹤0.01% 767
2019
Q3
$4K Buy
73
+1
+1% +$57 ﹤0.01% 855
2019
Q2
$4K Hold
72
– – ﹤0.01% 1036
2019
Q1
$4K Hold
72
– – ﹤0.01% 1258
2018
Q4
$4K Buy
72
+1
+1% +$61 ﹤0.01% 1169
2018
Q3
$5K Hold
71
– – ﹤0.01% 1227
2018
Q2
$4K Hold
71
– – ﹤0.01% 1147
2018
Q1
$4K Buy
71
+1
+1% +$60 ﹤0.01% 1263
2017
Q4
$4K Hold
70
– – ﹤0.01% 1341
2017
Q3
$4K Hold
70
– – ﹤0.01% 1322
2017
Q2
$4K Buy
70
+1
+1% +$57 ﹤0.01% 1347
2017
Q1
$4K Buy
+69
New +$3.74K ﹤0.01% 1337

Other funds holding PPH

Financial Architects (New Jersey)'s PPH Position: Q3 2020 in Review

Financial Architects (New Jersey) sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2020, closing a stake of 74 shares — an estimated $5K sold.

Financial Architects (New Jersey) first reported a position in PPH in Q1 2017 and held it in 14 quarters. The position peaked at $5K in Q2 2020. 47 funds tracked by Wall St. Rank hold PPH as of Q3 2020.

  • Financial Architects (New Jersey) reported no remaining VanEck Pharmaceutical ETF position as of Q3 2020 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 74 VanEck Pharmaceutical ETF shares in Q3 2020, an estimated $5K.
  • Financial Architects (New Jersey) first reported a position in VanEck Pharmaceutical ETF in Q1 2017 and held it in 14 quarters.
  • Financial Architects (New Jersey)'s VanEck Pharmaceutical ETF position peaked at $5K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2020.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2020, filed 9 Nov 2020.